You're viewing a free preview.You're viewing a free preview — a sample of each dataset.
Companies
The longevity science company universe by segment, stage, geography and capital raised.
739 companies tracked
| Company | Focus area | Funding |
|---|---|---|
| Immunis | Rejuvenation & Regenerative Medicine | $25M+ |
| Muna Therapeutics | Neurodegeneration & CNS | $73M+ |
| NeuroXT | Diagnostics & Biomarkers | — |
| Avai Bio | Rejuvenation & Regenerative Medicine | — |
| Austrianova | Cell & Gene Therapy | — |
| XellSmart | Neurodegeneration & CNS | — |
| MODAG | Neurodegeneration & CNS | EUR 12M+ |
| Veradermics | Rejuvenation & Regenerative Medicine | $294.8M+ |
| Jellatech | Rejuvenation & Regenerative Medicine | $3.5M |
| Oxford Healthspan | Senolytics & Damage Clearance | — |
Showing 10 of 739 companies
7-day free trial · already have an account?
Peek at other modules
News Feed
Daily longevity science headlines — aging research, deals, trials, and policy — with AI summaries.
Funding Tracker
Every disclosed longevity science round — size, stage and the investors behind it.
Clinical Trials
Longevity science and aging research trials by phase, sponsor, status and indication.
People & Movers
Who is joining, leaving and founding across longevity science and aging research.
Research
Peer-reviewed aging research distilled into investor-relevant takeaways.
Regulatory
FDA, EMA and policy developments that move aging research and the longevity market.